A U.S. appeals court has denied a request from Roche (OTCQX:RHHBY+0.6%) unit Genentech to stop Amgen (AMGN +2.7%) from selling its Avastin biosimilar Mvasi (bevacizumab-awwb) while it appeals a lower court ruling allowing sales to proceed.
It also failed in its attempt to halt sales of Amgen’s Herceptin biosimilar Kanjinti (trastuzumab-anns).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.